---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-23-000119"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2023-12-20T23:59:59+00:00"
generated_at: "2026-06-07T09:49:56.221704+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Evolus signs exclusive deal with Symatese for four dermal fillers in Europe; issues 610,000 shares

## Summary
- Exclusive rights to distribute Lift, Smooth, Sculpt, and Lips fillers under Estyme® brand in 50 European countries.
- Consideration includes 610,000 common shares to Symatese and up to €3.1M in milestone payments.
- European regulatory approvals expected H2 2024; commercialization targeted for 2025.
- No material impact on 2025 profitability target; company to pre-announce Q4/FY 2023 results and 2024 guidance in January.
- Evolus licenses Nuceiva® to Symatese for France; sub-licenses Estyme® distribution in France to Symatese subsidiary.

## SEC filing metadata
- accession: 0001570562-23-000119
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2023-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056223000119/0001570562-23-000119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056223000119/eols-20231220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-23-000119
- JSON: https://secwatch.observer/filing/0001570562-23-000119.json
- Plain text: https://secwatch.observer/filing/0001570562-23-000119.txt

## Key facts
- Material Agreements
  Evolus, Inc. entered into License, Supply and Distribution Agreement with Symatese Aesthetics S.A.S. valued at 610,000 shares of the Company’s common stock (effective 2023-12-20).
  - Action: entry
  - Agreement: license
  - Counterparty: Symatese Aesthetics S.A.S.
  - Value: 610,000 shares of the Company’s common stock
  - Effective: 2023-12-20
  source text: On December 20, 2023, Evolus Pharma B.V. (“Evolus Europe”), a wholly owned subsidiary of Evolus, Inc. (the “Company”) and Symatese Aesthetics S.A.S. (“Symatese”), entered into a License, Supply and Distribution Agreement (the “Agreement”), pursuant to which Symatese granted to Evolus Europe an exclusive right to commercialize and distribute four dermal filler product candidates
  evidence_url: https://www.sec.gov/Archives/edgar/data/1570562/000157056223000119/0001570562-23-000119-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.